• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2024

    8/11/23 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email

    Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023.

    Commenting on the first quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said:

    "This quarter we continue to see the impact of consumers shifting their spend from goods to experiences and services and reallocation of spending related to the high cost of living. Due to these shifting consumer trends, we have added a new position to the Company, Chief Strategic and Commercial Officer, to oversee and drive market strategy and revenue opportunities."

    "Our production is performing efficiently, and we are managing production volumes in line with sales demand to control costs."

    "I am optimistic about the Company's future as we continue to build brand awareness to our naturally derived high value nutritional products."

    First Quarter Fiscal 2024

    Cyanotech reported net sales of $5,146,000 for the first quarter of fiscal 2024 compared to $6,716,000 for the first quarter of fiscal 2023, a decrease of 23.4%. Gross profit was $1,532,000, with gross profit margin of 29.8%, compared to gross profit of $2,318,000, with gross profit margin of 34.5%. Operating loss for the first quarter of fiscal 2024 was $1,209,000 compared to operating loss of $425,000 in the same period of the prior year. Net loss for the current fiscal quarter was $1,369,000, or $0.22 per diluted share, compared to net loss of $472,000, or $0.08 per diluted share, for the same period of the prior year.

    Trailing Twelve Months

    For the trailing twelve months ended June 30, 2023, compared to the trailing twelve months ended June 30, 2022, net sales were $21,607,000 compared to $33,720,000, respectively. Gross profit was $6,473,000, with gross profit margin of 30.0%, compared to $12,212,000 and 36.2%. Net loss was $4,337,000, or $0.69 per diluted share, compared to net income of $1,161,000, or $0.19 per diluted share.

    Please review the Company's Form 10-Q for the period ended June 30, 2023 for more detailed information.

    ---------------

    — Cyanotech will host a virtual broadcast at 8:00 PM EDT on Monday, August 14, 2023 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to [email protected] before 12 p.m. (noon) EDT on Monday, August 14, 2023. The Company will respond only to relevant questions relating to the Company's first quarter fiscal 2024 financial performance and will not be accepting any questions or comments during the broadcast.

    To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.

    ---------------

    About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company's mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech's BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity*. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe ("GRAS") for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit www.cyanotech.com for more information.

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

    "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission.

    Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company's Form 10-Q for the first quarter fiscal 2024 ended June 30, 2023, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such, the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission.

    CYANOTECH CORPORATION

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share amounts)

    (Unaudited)

     

     

     

    June 30,

    2023

     

    March 31,

    2023

    ASSETS

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash

     

    $

    648

     

     

    $

    974

     

    Accounts receivable, net of allowance for credit losses of $11 as of June 30, 2023 and $64 as of March 31, 2023

     

     

    1,794

     

     

     

    1,331

     

    Inventories

     

     

    10,506

     

     

     

    10,707

     

    Prepaid expenses and other current assets

     

     

    378

     

     

     

    484

     

    Total current assets

     

     

    13,326

     

     

     

    13,496

     

     

     

     

     

     

     

     

    Equipment and leasehold improvements, net

     

     

    11,065

     

     

     

    11,366

     

    Operating lease right-of-use assets, net

     

     

    4,656

     

     

     

    4,776

     

    Other assets

     

     

    85

     

     

     

    90

     

    Total assets

     

    $

    29,132

     

     

    $

    29,728

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    1,721

     

     

    $

    1,021

     

    Accrued expenses

     

     

    821

     

     

     

    1,101

     

    Customer deposits

     

     

    77

     

     

     

    89

     

    Operating lease obligations, current portion

     

     

    494

     

     

     

    483

     

    Line of credit

     

     

    1,770

     

     

     

    1,540

     

    Line of credit – related party

     

     

    750

     

     

     

    500

     

    Current maturities of long-term debt

     

     

    3,313

     

     

     

    3,369

     

    Total current liabilities

     

     

    8,946

     

     

     

    8,103

     

     

     

     

     

     

     

     

    Long-term debt, less current maturities

     

     

    1,000

     

     

     

    1,000

     

    Long-term operating lease obligations

     

     

    4,146

     

     

     

    4,275

     

    Other long-term liabilities

     

     

    —

     

     

     

    3

     

    Total liabilities

     

     

    14,092

     

     

     

    13,381

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

    Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding

     

     

    —

     

     

     

    —

     

    Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,291,086 shares at June 30, 2023 and 6,271,971 shares at March 31, 2023

     

     

    126

     

     

     

    125

     

    Additional paid-in capital

     

     

    33,917

     

     

     

    33,856

     

    Accumulated deficit

     

     

    (19,003

    )

     

     

    (17,634

    )

    Total stockholders' equity

     

     

    15,040

     

     

     

    16,347

     

    Total liabilities and stockholders' equity

     

    $

    29,132

     

     

    $

    29,728

     

    CYANOTECH CORPORATION

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except per share amounts)

    (Unaudited)

     

     

     

    Three Months Ended

    June 30,

     

     

    2023

     

    2022

     

     

     

     

     

     

     

    Net sales

     

    $

    5,146

     

     

    $

    6,716

     

    Cost of sales

     

     

    3,614

     

     

     

    4,398

     

    Gross profit

     

     

    1,532

     

     

     

    2,318

     

     

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

     

    General and administrative

     

     

    1,274

     

     

     

    1,329

     

    Sales and marketing

     

     

    1,276

     

     

     

    1,168

     

    Research and development

     

     

    191

     

     

     

    246

     

    Total operating expenses

     

     

    2,741

     

     

     

    2,743

     

     

     

     

     

     

     

     

    Loss from operations

     

     

    (1,209

    )

     

     

    (425

    )

     

     

     

     

     

     

     

    Interest expense, net

     

     

    (160

    )

     

     

    (44

    )

     

     

     

     

     

     

     

    Loss before income taxes

     

     

    (1,369

    )

     

     

    (469

    )

     

     

     

     

     

     

     

    Income tax expense

     

     

    —

     

     

     

    3

     

     

     

     

     

     

     

     

    Net loss

     

    $

    (1,369

    )

     

    $

    (472

    )

     

     

     

     

     

     

     

    Net loss per share:

     

     

     

     

     

     

    Basic

     

    $

    (0.22

    )

     

    $

    (0.08

    )

    Diluted

     

    $

    (0.22

    )

     

    $

    (0.08

    )

     

     

     

     

     

     

     

    Shares used in calculation of net loss per share:

     

     

     

     

     

     

    Basic

     

     

    6,290

     

     

     

    6,204

     

    Diluted

     

     

    6,290

     

     

     

    6,204

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230811829260/en/

    Get the next $CYAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/3/24 3:27:06 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/1/24 4:42:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/27/24 1:33:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    SEC Filings

    See more
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      5/8/25 3:56:11 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      2/11/25 4:01:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      12/16/24 1:53:10 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Financials

    Live finance-specific insights

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by VP of Sales Brand Jennifer Kimberly

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:06:36 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, HR, Secretary Nordin Amy Beth

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:04:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, Operations Jensen Glenn

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:02:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CYAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      10/3/24 6:39:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/12/24 12:25:52 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/6/24 12:45:58 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care